BioCentury | Jul 8, 2020
Finance

VarmX attracts investor syndicate with financial reserves to support coagulation company beyond €32M series B

...coagulation Factor X in preclinical development to treat spontaneous bleeding in patients treated with oral Factor Xa...
...risk, cardiac arrest and sudden death. In addition, because VMX-C001 doesn’t directly interact with the Factor Xa...
...anticoagulant used. Andexxa’s label is limited to reversing the effects of the two best-selling oral Factor Xa...
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...triple-digit premium, Alexion is signaling that it believes its commercial expertise can boost sales of Factor Xa...
...its $5 billion in 2019 sales, will obtain global rights to Portola’s Andexxa recombinant coagulation factor Xa...
...and the drug reaches markets in additional European territories and Japan. The introduction of generic Factor Xa...
BioCentury | Jul 8, 2019
Clinical News

July 8 Clinical Quick Takes: Hemophilia data from Sangamo-Pfizer, Novo; plus GamaMabs, Xarelto and more

...thromboembolism (VTE) in patients under age 17. On the primary endpoints, patients on the direct Factor Xa...
...& Johnson NIH Novo Nordisk A/S Otsuka Holdings Co. Ltd. Pfizer Inc. Sangamo Therapeutics Inc. Servier Anti-Mullerian hormone receptor type II (AMHR2) Factor VIII Factor Xa Tissue...
BioCentury | Apr 26, 2019
Company News

European regulatory roundup: CHMP opinions and a Portola approval

...is a modified human Factor Xa protein that acts as a decoy to target and sequester Factor Xa...
...cancer 2 early onset (BRCA2) Complement 5 (C5) Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Factor VIII Factor Xa Granulocyte...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...PDUFA date 6/23/19 Portola Pharmaceuticals Inc. (NASDAQ:PTLA) Ondexxya andexanet alfa Reverse the anticoagulant activity of Factor Xa...
BioCentury | Mar 8, 2019
Company News

CHMP recommendations include Ondexxya, Waylivra

...is a modified human Factor Xa protein that acts as a decoy to target and sequester Factor Xa...
BioCentury | Mar 1, 2019
Company News

CHMP recommendations include Ondexxya, Waylivra

...is a modified human Factor Xa protein that acts as a decoy to target and sequester Factor Xa...
BioCentury | Feb 7, 2019
Politics & Policy

J&J to include drug pricing in TV ads

...is $447.99 for a month’s supply. J&J posted $1.9 billion in sales of the direct Factor Xa...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Pharmaceuticals Inc. as an example. Last year, Portola launched Andexxa andexanet alfa, an antidote to factor Xa...
BioCentury | Jan 4, 2019
Clinical News

Portola gains next-generation Andexxa approval, aims for wider U.S. launch

...FDA approved a Prior Approval Supplement for Andexxa recombinant coagulation factor Xa inactivated-zhzo (formerly andexanet alfa) to...
...granted accelerated approval to the modified human Factor Xa protein to reverse the anticoagulant activity of Factor Xa...
...Francisco, Calif. Product: Andexxa andexanet alfa Business: Hematology Sandi Wong Andexxa, Indexxa, andexanet alfa (PRT064445, PRT4445) Portola Pharmaceuticals Inc. Factor Xa...
Items per page:
1 - 10 of 609